Barclays Maintains Equal-Weight on Gilead Sciences, Lowers Price Target to $76
Gilead Sciences, Inc. +2.17%
Gilead Sciences, Inc. GILD | 88.16 | +2.17% |
Barclays analyst Carter Gould maintains Gilead Sciences (NASDAQ:
GILD) with a Equal-Weight and lowers the price target from $80 to $76.